Efficacy of remdesivir for hospitalized COVID-19 patients with end stage renal disease
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2021.02.10.21251527: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The Institutional Review Board of the Hospital approved the study. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources Clinical risk factors modeled included maximum oxygen requirements, peak and discharge d dimer levels, CRP levels at the onset, peak and discharge, receipt of disease-specific treatment (monoclonal antibody, dexamethasone, antibiotics), and discharge disposition. dexamethasone, antibiotics),suggested: NoneResults from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data …
SciScore for 10.1101/2021.02.10.21251527: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The Institutional Review Board of the Hospital approved the study. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources Clinical risk factors modeled included maximum oxygen requirements, peak and discharge d dimer levels, CRP levels at the onset, peak and discharge, receipt of disease-specific treatment (monoclonal antibody, dexamethasone, antibiotics), and discharge disposition. dexamethasone, antibiotics),suggested: NoneResults from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Our study has several limitations. The sample size was small and may not have been powered adequately to detect a difference. All of our patients were on intermittent HD. It is difficult to ascertain the benefit and safety of remdesivir in patients with a history of kidney transplant or chronic kidney disease stage 4 or 5 that are not on dialysis. Even though there was a baseline difference in the remdesivir group that received dexamethasone, there was no significant change in CRP levels, length of stay, mortality, or d dimer levels. However, it is unclear if the higher concurrent use of dexamethasone in the remdesivir group eclipsed potential differences in any of the outcomes. Some patients in the non-remdesivir group did not receive dexamethasone as they presented earlier in the year when the use of dexamethasone was not approved. For the same reason, some of these patients also received convalescent plasma, hydroxychloroquine, and azithromycin. In conclusion, the addition of remdesivir to dexamethasone to treat COVID-19 in patients with ESRD had no significant effect on length of stay, oxygen requirements, mortality, CRP, and d dimer levels. Further studies are needed to study the effects of remdesivir in patients with CKD stage 4 or 5 that are not on HD. Key issues to be elucidated include the effect on renal function and the risk-benefit of a 3-day, 5-day, and 10-day regimen. Large-scale studies are also needed further to determine remdesivir’s role in this vulnerable, ...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-